Can you take more than 2.4 mg of Wegovy — and what the 7.2 mg approval means for you

Where the 7.2 mg approval came from, and what the trial data showed

The starting point here is the regulatory record, not speculation. In January 2026 the MHRA authorised a 7.2 mg maintenance dose of semaglutide under the Wegovy licence, initially supplied as three 2.4 mg pens taken weekly. Then, on 14 April 2026, the MHRA went a step further and approved a dedicated single-dose 7.2 mg pen, one pre-set weekly injection with an auto-dosing mechanism and a built-in covered needle that locks after use. You can read the announcement directly on GOV.UK's news page for the 7.2 mg Wegovy pen approval.

The evidence behind that decision is meaningful. Trials at 7.2 mg reported average body-weight reduction of around 20.7% over 72 weeks. To put that in context, the STEP 1 trial (the landmark study that got 2.4 mg licensed) showed roughly 15% average weight loss over 68 weeks, as published in the New England Journal of Medicine. A roughly five-percentage-point improvement at the higher dose is clinically meaningful, and it starts to narrow the gap with tirzepatide's results at its highest strength. The trial data mattered; the MHRA reviewed it and approved the dose. That sequence is worth knowing.

One important boundary: the 7.2 mg pen approval is specifically for adults with obesity, defined as BMI 30 or above. It does not apply to people using semaglutide for cardiovascular risk reduction under the separate indication for that condition. If you are exploring how the full Wegovy dose schedule works, that context shapes the whole picture.

How the dose ladder actually reaches 7.2 mg, no shortcuts

The temptation, once you know a higher dose exists, is to want to jump to it. That is not how the medicine works, and it is not how prescribers approach it. Treatment opens at 0.25 mg, a dose whose job is settling your system rather than producing maximum effect. From there, the schedule moves upward in roughly four-week steps: 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg as the previous standard maintenance dose, and now 7.2 mg as the extended maximum.

Each rung exists because semaglutide's most common side effects (nausea, constipation, reflux, and occasional vomiting) are dose-related and tend to be most noticeable after a step up. Rushing through the ladder does not help; it tends to make those side effects harder to manage and can prompt a step back down, which actually slows progress. The prescriber's job is to find the highest dose you tolerate well, which may or may not be the maximum. Some people do very well at 1.7 mg and have no clinical reason to push further. Others plateau at 2.4 mg and, from April 2026 onwards, have a licensed option to go higher with proper clinical oversight, as explained on the page covering what a Wegovy dose higher than 2.4 mg involves.

For anyone curious about whether the extra weight loss at higher doses justifies the step up, the page on whether you lose more weight at 2.4 mg covers the dose-response relationship in more detail.

What 'more than 2.4 mg' does not mean, two common misreads

The first misread is the idea that you can simply take two doses close together to replicate a higher-dose effect. That is not safe and not recommended. Doubling up on injections carries a real risk of severe nausea, vomiting, and hypoglycaemia in people also managing blood sugar. The page on taking two doses of Wegovy deals with this question directly and clearly.

The second misread is conflating Wegovy with Ozempic. Both contain semaglutide, but Ozempic is licensed in the UK for type 2 diabetes, not weight management. People sometimes assume an Ozempic dose above 2.4 mg represents a route to higher-dose weight-loss treatment. It does not. The licensed weight-management product is Wegovy, and the 7.2 mg approval applies to it specifically.

It is also worth noting that cost can shift noticeably as doses increase. Eli Lilly raised Mounjaro's UK list price substantially from September 2025, and Wegovy pricing moves in a similar direction at higher strengths. If cost is a factor in your thinking, the Wegovy pricing page gives an honest picture of what to expect at different doses. Knowing that before your consultation means the conversation with a prescriber can focus on clinical fit rather than surprises.

The role of clinical assessment, and what to do next

Nothing in this page should replace a conversation with a prescriber. The 7.2 mg dose is approved; whether it is right for any particular person depends on their health history, current dose, how their body has responded so far, and any medicines they take alongside Wegovy. Semaglutide is a prescription-only medicine under the Human Medicines Regulations, and a prescriber decides suitability, not a checklist, and not an algorithm.

A question our prescribers hear regularly is whether moving to a higher dose is something they can request mid-treatment. The answer is yes, it can be discussed, but the prescriber will want to see evidence of how the current dose is being tolerated and what progress has been made. That is good medicine, not a barrier. If you are already on treatment elsewhere and want to continue (or step up) with proper clinical oversight, the weight-loss treatment overview explains the options available through a GPhC-registered private pharmacy. One practical note: if you are thinking about starting a consultation around a pay date or a bank holiday Monday, orders placed before 12pm on working days are dispatched the same day once clinically approved, so timing does matter for delivery.

The full Wegovy guide covers the medicine from licence to lifestyle support if you want a broader foundation before speaking to a prescriber. And if specific questions remain, the FAQs page is a good next stop. When you are ready, start your free consultation and a named prescriber will review your answers the same day.